Introduction
The discovery of the gene that causes Huntington's disease (HD) in 1993 sparked tremendous hope that a cure was just around the corner [1] . However, this initial enthusiasm was soon diminished and a cure remains elusive as current treatments reduce the symptoms but do not prevent neuronal loss. Unexpectedly, the faulty gene product, mutant huntingtin (mtHtt), is an extremely large protein of 350 kDa and might act as a scaffold protein regulating vesicle and organelle trafficking and signaling pathways. Although the protein is mostly cytoplasmic, it is also present in smaller amounts in multiple subcellular compartments including the plasma membrane, nucleus, endoplasmic reticulum, endocytic vesicles, Golgi and mitochondria, and it interferes with multiple cellular pathways [2] [3] [4] [5] [6] [7] [8] [9] [10] . Thus, these properties have made it difficult to pin down the normal and neurotoxic function(s) of huntingtin (Htt). Now, new evidence has emerged that implicates malfunctioning mitochondria in HD pathogenesis. Here, we focus on these new observations because they might bring us closer to effective treatments that can either slow or stall the relentless neuronal loss in HD. Specifically, we focus on the potential pathways by which mtHtt could cause mitochondrial dysfunction.
HD is an autosomal-dominant neurodegenerative disorder that affects 30 000 patients in the United States alone. Clinical symptoms of HD include progressive chorea (involuntary dance-like movements), rigidity, weight loss, dementia, seizures and psychiatric disturbances such as depression, withdrawal and irritability. Symptoms result from the selective loss of long projection neurons, known as medium spiny neurons, which are g-aminobutyric acid (GABA)-releasing neurons in the striatal brain regions that control movement, memory and emotions. In addition, early neuronal loss and dysfunction occurs not only in the striatum but also in the cortex in HD patients [11] . HD is slowly progressive and patients succumb to the disease within 15-20 years of symptom onset.
HD is one of nine neurodegenerative disorders caused by an abnormal expansion of CAG repeats that encode a poly-glutamine stretch. A poly-glutamine expansion of <35 in the N terminus of Htt is normal and does not cause disease. However, Htt with an abnormal stretch of 36-39 glutamines results in incomplete penetrance, with some individuals developing HD whereas others do not, and 40 or more glutamines results in HD with full penetrance [12] . Clinical symptoms start in most cases between the ages of 30 and 40, but the disease can strike, in some rare cases, young patients whose Htt molecule has 60 or more glutamine residues [13] . Thus, there is an inverse relationship between the length of the poly-glutamine stretch and age of disease onset, with longer glutamine stretches resulting in earlier disease onset and increased severity.
A question that has long occupied neurologists is why disease onset is late despite the presence of the mutation at birth. In addition to the inherited CAG expansion, new observations indicate that somatic CAG expansions occur during aging in the striatum, the brain region that is most affected in HD, modulating the disease onset and progression [14] . The underlying mechanism responsible for the somatic expansion of CAG is activation of the errorprone base-pair-repair enzyme 7,8-dihydro-8-oxoguanine-DNA glycosylase 1 (OGG1) that is induced by oxidative stress [14] . As oxidative damage accumulates with age, a somatic expansion of the CAG repeat might trigger the delayed onset of the disorder. 
